Research programme: CAR-T anti-cancer therapeutics - Helix BioPharma

Drug Profile

Research programme: CAR-T anti-cancer therapeutics - Helix BioPharma

Alternative Names: Anti-CEACAM6 CAR-T cell therapy - Helix BioPharma; Anti-VEGFR2 CAR-T cell therapy - Helix BioPharma; Bispecific CAR-T cell therapy - Helix BioPharma; Chimeric Antigen Receptor-based cell therapies - Helix BioPharma; Tumour defence attackers - Helix BioPharma

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Helix BioPharma
  • Class CAR-T cell therapies; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics
  • Mechanism of Action Carcinoembryonic antigen modulators; Immunomodulators; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 17 Mar 2017 Preclinical trials in Haematological malignancies in Canada (Parenteral) (Helix BioPharma pipeline, March 2017)
  • 27 Feb 2017 Helix BioPharma in-licenses Anti-CEACAM6 antibody from National Research Council of Canada for development of CAR-T based therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top